PLASMAPHERESIS AND INTRAVENOUS IMMUNE GLOBULIN PROVIDES EFFECTIVE RESCUE THERAPY FOR REFRACTORY HUMORAL REJECTION AND ALLOWS KIDNEYS TO BE SUCCESSFULLY TRANSPLANTED INTO CROSS-MATCH-POSITIVE RECIPIENTS

Background. Hyperacute rejection (HAR) and acute humoral rejection (AHR) remain recalcitrant conditions without effective treatments, and usually result in graft loss.Plasmapheresis (PP) has been shown to remove HLA- specific antibody (Ab) in many different clinical settings. Intravenous gamma globulin (IVIG) has been used to suppress alloantibody and modulate immune responses. Our hypothesis was that a combination of PP and IVIG could effectively and durably remove donor-specific, anti-HLA antibody (Ab), rescuing patients with established AHR and preemptively desensitizing recipients who had positive cross-matches with a potential live donor. Methods. The study patients consisted of seven live donor kidney transplant recipients who experienced AHR and had donor-specific Ab (DSA) for one or more mismatched donor HLA antigens. The patients segregated into two groups: three patients were treated for established AHR (rescue group) and four cross-match-positive patients received therapy before transplantation (preemptive group). Results. Using PP/IVIG we have successfully reversed established AHR in three patients. Four patients who were cross-match-positive (3 by flow cytometry and 1 by cytotoxic assay) and had DSA before treatment underwent successful renal transplantation utilizing their live donor. The overall mean creatinine for both treatment groups is 1.4±0.8 with a mean follow up of 58±40 weeks (range 17–116 weeks). Conclusions. In this study, we present seven patients for whom the combined therapies of PP/IVIG were successful in reversing AHR mediated by Ab specific for donor HLA antigens. Furthermore, this protocol shows promise for eliminating DSA preemptively among patients with low-titer positive antihuman globulin-enhanced, complement-dependent cytotoxicity (AHG-CDC) cross-matches, allowing the successful transplantation of these patients using a live donor without any cases of HAR.

[1]  R. Colvin,et al.  Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. , 1998, Transplantation.

[2]  J. Sageshima,et al.  Postoperative production of anti-donor antibody and early graft loss due to vascular rejection in renal transplantation. , 1998, Transplantation proceedings.

[3]  R. Kapoor,et al.  Donor specific CDC lymphocyte crossmatch and five year allograft survival. , 1998, Transplantation proceedings.

[4]  M. Fishbein,et al.  Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. , 1998, Transplantation.

[5]  P. Kimball,et al.  Flow cross-matching identifies patients at risk for postoperative elaboration of cytotoxic antibodies. , 1998, Transplantation.

[6]  M. Rial,et al.  Complementary data about the inhibitory effects of intravenous immunoglobulins in vitro and in vivo. , 1997, Transplantation.

[7]  J. Kalil,et al.  Identification of patients at high risk of graft loss by pre- and posttransplant monitoring of anti-HLA class I IgG antibodies by enzyme-linked immunosorbent assay. , 1997, Transplantation.

[8]  M. Bewick,et al.  Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation , 1996, The Lancet.

[9]  G. Tufveson,et al.  Pretransplantation plasmapheresis in HLA-sensitized patients: five years experience. , 1995, Transplantation proceedings.

[10]  R. Vaughan,et al.  Presence of IgG HLA antibodies in patients with long-surviving renal allografts. , 1995, Transplantation proceedings.

[11]  P. Dědič,et al.  Treatment of acute humoral rejection in kidney transplantation with plasmapheresis. , 1995, Transplantation proceedings.

[12]  J. Haymann,et al.  Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. , 1995, Transplantation proceedings.

[13]  N. Amada,et al.  Beneficial effects of double-filtration plasmapheresis on living related donor renal transplantation in presensitized recipients. , 1995, Transplantation proceedings.

[14]  J. Nally,et al.  Pretransplant removal of anti-HLA antibodies by plasmapheresis and continued suppression on cyclosporine-based therapy after heart-kidney transplant. , 1994, Transplantation proceedings.

[15]  S. Jordan,et al.  Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. , 1994, Clinical and experimental immunology.

[16]  U. Andersson,et al.  Pooled Human IgG Modulates Cytokine Production in Lymphocytes and Monocytes , 1994, Immunological reviews.

[17]  L. Czer,et al.  Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. , 1994, Transplantation.

[18]  B. Julian,et al.  RENAL RETRANSPLANTATION: THE ROLE OF RACE, QUADRUPLE IMMUNOSUPPRESSION, AND THE FLOW CYTOMETRY CROSS‐MATCH , 1994, Transplantation.

[19]  M. Kazatchkine,et al.  Treatment of autoimmune diseases with normal immunoglobulin through manipulation of the idiotypic network , 1993, Clinical and experimental immunology.

[20]  J. Haymann,et al.  SUPPRESSION OF HLA‐SPECIFIC ALLOANTIBODIES BY HIGH‐DOSE INTRAVENOUS IMMUNOGLOBULINS (IVIg): A POTENTIAL TOOL FOR TRANSPLANTATION OF IMMUNIZED PATIENTS , 1993, Transplantation.

[21]  R. Lechler,et al.  Renal transplantation following immunoadsorption in highly sensitized recipients. , 1993, Transplantation.

[22]  R. Bray.  Flow Cytometry in the Transplant Laboratory , 1993, Annals of the New York Academy of Sciences.

[23]  À. Argilés,et al.  Disappearance of anti-HLA antibodies in highly sensitized patients treated with erythropoietin. , 1992, Transplantation proceedings.

[24]  N. Ghabra.  The need to reduce cyclosporine dose when switching renal transplant patients from solution form to capsule form , 1992 .

[25]  J. Marchalonis,et al.  Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E. Möller,et al.  FEWER ACUTE REJECTION EPISODES AND IMPROVED OUTCOME IN KIDNEY‐TRANSPLANTED PATIENTS WITH SELECTION CRITERIA BASED ON CROSSMATCHING , 1992, Transplantation.

[27]  P. Halloran,et al.  THE SIGNIFICANCE OF THE ANTI–CLASS I RESPONSE , 1992, Transplantation.

[28]  J. Dwyer.  Manipulating the immune system with immune globulin. , 1992, The New England journal of medicine.

[29]  J. C. Houwelingen,et al.  PROGNOSTIC INDICES TO PREDICT SURVIVAL OF FIRST AND SECOND RENAL ALLOGRAFTS , 1991, Transplantation.

[30]  D. Dunn,et al.  Risk factors for second renal allografts immunosuppressed with cyclosporine. , 1991, Transplantation.

[31]  W. Kupin,et al.  Removal of lymphocytotoxic antibodies by pretransplant immunoadsorption therapy in highly sensitized renal transplant recipients. , 1991, Transplantation.

[32]  P. Gjörstrup.  Anti-HLA antibody removal in hyperimmunized ESRF patients to allow transplantation. The Collaborative Study Group on Anti-HLA Antibody Removal. , 1991, Transplantation proceedings.

[33]  J. Soulillou,et al.  EFFECT OF PROTEIN A IMMUNOADSORPTION ON PANEL LYMPHOCYTE REACTIVITY IN HYPERIMMUNIZED PATIENTS AWAITING A KIDNEY GRAFT , 1990, Transplantation.

[34]  P. Fauchald,et al.  Plasma exchange and immunoadsorption prior to renal transplantation in allosensitized patients. , 1990, Transplantation proceedings.

[35]  J. Bergström,et al.  Measures to decrease HLA antibodies in immunized patients awaiting kidney transplantation. , 1990, Transplantation proceedings.

[36]  P. Morris,et al.  Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. , 1989, Transplantation.

[37]  K. Welsh,et al.  REMOVAL OF ANTI-HLA ANTIBODIES BY EXTRACORPOREAL IMMUNOADSORPTION TO ENABLE RENAL TRANSPLANTATION , 1989, The Lancet.

[38]  M. Kazatchkine,et al.  Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. , 1988, Clinical and experimental immunology.

[39]  E. Berntorp,et al.  Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. , 1988, The New England journal of medicine.

[40]  O. Jonasson,et al.  THE RELATIONSHIP BETWEEN FLOW CYTOMETER CROSSMATCH RESULTS AND SUBSEQUENT REJECTION EPISODES IN CADAVER RENAL ALLOGRAFT RECIPIENTS , 1988, Transplantation.

[41]  J. Kurtzberg,et al.  Treatment of platelet alloimmunization with intravenous immunoglobulin. Two case reports and review of the literature. , 1987, The American journal of medicine.

[42]  R. Gokal,et al.  Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome. , 1987, Transplantation.

[43]  A. Gaber,et al.  T cell immunofluorescence flow cytometry cross-match results in cadaver donor renal transplantation. , 1987, Transplantation proceedings.

[44]  M. Kazatchkine,et al.  Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Danovitch,et al.  Flow cytometry crossmatching in human cadaver kidney transplantation. , 1987, Transplantation proceedings.

[46]  J. Chapman,et al.  IMMUNOGLOBULIN CLASS AND SPECIFICITY OF ANTIBODIES CAUSING POSITIVE T CELL CROSSMATCHES: RELATIONSHIP TO RENAL TRANSPLANT OUTCOME , 1986, Transplantation.

[47]  K. Welsh,et al.  RENAL TRANSPLANTATION AFTER REMOVAL AND PREVENTION OF RESYNTHESIS OF HLA ANTIBODIES , 1984, The Lancet.

[48]  C. Cardella,et al.  SUCCESSFUL RENAL TRANSPLANTATION IN PATIENTS WITH T-CELL REACTIVITY TO DONOR , 1982, The Lancet.

[49]  P. Morris,et al.  RENAL TRANSPLANTATION AND B-CELL CROSS-MATCHES WITH AUTOANTIBODIES AND ALLOANTIBODIES , 1977, The Lancet.

[50]  Evans Da.  Letter: Coeliac disease and HL-A8. , 1973 .

[51]  P. Terasaki,et al.  Significance of the positive crossmatch test in kidney transplantation. , 1969, The New England journal of medicine.

[52]  P. Morris,et al.  "Hyperacute" renal-homograft rejection in man. , 1968, The New England journal of medicine.

[53]  O. Fjeldborg,et al.  Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells , 1967 .

[54]  P. Ms,et al.  PROTECTION AGAINST RUBELLA , 1965 .

[55]  M ROBURN,et al.  Femoral neck fractures. , 1964, Lancet.

[56]  M. Christiaans,et al.  Donor-specific antibodies after transplantation by flow cytometry: relative change in fluorescence ratio most sensitive risk factor for graft survival. , 1998, Transplantation.

[57]  R. Vaughan,et al.  5-year follow-up of patients successfully transplanted after immunoadsorption to remove anti-HLA antibodies. , 1996, Nephron.

[58]  B. Charpentier,et al.  Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[59]  P. Halloran,et al.  The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. , 1990, Transplantation.

[60]  S. Piantadosi,et al.  A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. , 1990, Blood.

[61]  M. Kazatchkine,et al.  Antiidiotypic suppression of autoantibodies with normal polyspecific immunoglobulins. , 1989, Research in immunology.

[62]  J. Finlayson,et al.  Immunoglobulin G dimer: an idiotype-anti-idiotype complex. , 1988, Molecular immunology.

[63]  L. Sandu.  Letter: Corticosteroids in Landry-Guillain-Barré-Strohl syndrome. , 1974, Lancet.